Five-year overview

Five-year overview

DKK million

 

2021

 

2022

 

2023

 

2024

 

2025

 

Change
2024-25

Financial performance

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

140,800

 

176,954

 

232,261

 

290,403

 

309,064

 

6.4%

Sales growth as reported

 

10.9%

 

25.7%

 

31.3%

 

25.0%

 

6.4%

 

 

Sales growth in constant exchange rates1

 

13.8%

 

16.4%

 

35.6%

 

25.7%

 

10.3%

 

 

Operating profit

 

58,644

 

74,809

 

102,574

 

128,339

 

127,658

 

(0.5%)

Operating profit growth as reported

 

8.3%

 

27.6%

 

37.1%

 

25.1%

 

(0.5%)

 

 

Operating profit growth in constant exchange rates1

 

12.7%

 

14.6%

 

43.7%

 

26.2%

 

6.0%

 

 

Depreciation, amortisation and impairment losses

 

6,025

 

7,362

 

9,413

 

19,107

 

21,982

 

15.0%

EBITDA1, 2

 

64,669

 

82,171

 

111,987

 

147,446

 

149,640

 

1.5%

EBITDA growth as reported1, 2

 

8.0%

 

27.1%

 

36.3%

 

31.7%

 

1.5%

 

 

EBITDA growth in constant exchange rates1, 2

 

12.0%

 

14.9%

 

42.4%

 

32.7%

 

7.3%

 

 

Net financials

 

436

 

(5,747)

 

2,100

 

(1,148)

 

2,882

 

 

Profit before income taxes

 

59,080

 

69,062

 

104,674

 

127,191

 

130,540

 

2.6%

Effective tax rate3

 

19.2%

 

19.6%

 

20.1%

 

20.6%

 

21.5%

 

 

Net profit

 

47,757

 

55,525

 

83,683

 

100,988

 

102,434

 

1.4%

Adjusted net profit1

 

49,146

 

57,370

 

86,229

 

110,557

 

116,407

 

 

Purchase of property, plant and equipment

 

6,335

 

12,146

 

25,806

 

47,164

 

60,140

 

28%

Purchase of intangible assets

 

1,050

 

2,607

 

13,090

 

4,145

 

29,973

 

623%

Cash used for acquisition of businesses

 

18,283

 

7,075

 

 

82,163

 

 

 

Free cash flow1

 

29,319

 

57,362

 

68,326

 

(14,707)

 

28,295

 

 

Total assets

 

194,508

 

241,257

 

314,486

 

465,630

 

542,902

 

17%

Net debt1

 

(5,031)

 

2,319

 

8,950

 

(69,713)

 

(95,424)

 

37%

Equity

 

70,746

 

83,486

 

106,561

 

143,486

 

194,047

 

35%

Financial ratios

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin3

 

83.2%

 

83.9%

 

84.6%

 

84.7%

 

81.0%

 

 

Sales and distribution costs in percentage of sales

 

26.3%

 

26.1%

 

24.4%

 

21.4%

 

20.8%

 

 

Research and development costs in percentage of sales

 

12.6%

 

13.6%

 

14.0%

 

16.6%

 

16.8%

 

 

Cash to earnings1

 

61.4%

 

103.3%

 

81.6%

 

(14.6%)

 

27.6%

 

 

Operating margin3

 

41.7%

 

42.3%

 

44.2%

 

44.2%

 

41.3%

 

 

Net profit margin3

 

33.9%

 

31.4%

 

36.0%

 

34.8%

 

33.1%

 

 

Return on invested capital1

 

69.0%

 

73.6%

 

88.5%

 

63.9%

 

39.3%

 

 

Share performance and capital allocation

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share/ADR in DKK3

 

10.40

 

12.26

 

18.67

 

22.67

 

23.06

 

1.7%

Diluted earnings per share/ADR in DKK3

 

10.37

 

12.22

 

18.62

 

22.63

 

23.03

 

1.8%

Adjusted diluted earnings per share/ADR in DKK1

 

10.67

 

12.62

 

19.18

 

24.77

 

26.17

 

5.7%

Total number of shares (million), end of year

 

4,620

 

4,560

 

4,510

 

4,465

 

4,465

 

0.0%

Dividend per share in DKK4

 

5.20

 

6.20

 

9.40

 

11.40

 

11.70

 

2.6%

Total dividend (DKK million)4

 

23,711

 

27,950

 

41,987

 

50,683

 

51,975

 

2.5%

Dividend payout ratio3

 

49.6%

 

50.3%

 

50.2%

 

50.2%

 

50.7%

 

 

Share repurchases (DKK million)

 

19,447

 

24,086

 

29,924

 

20,181

 

1,388

 

(93%)

Closing share price (DKK)

 

368

 

469

 

698

 

624

 

325

 

(48%)

Sustainability performance

 

 

 

 

 

 

 

 

 

 

 

 

Total number of patients reached (in millions)5

 

34.9

 

36.9

 

41.6

 

45.2

 

45.6

 

1%

Total number of employees (headcount)

 

48,478

 

55,185

 

64,319

 

77,349

 

69,505

 

(10%)

Total GHG6 emissions – market-based (1,000 tonnes CO2e)

 

 

 

1,836

 

2,261

 

2,690

 

19%

Plastic footprint per patient (kg/patient)

 

 

 

 

0.38

 

0.36

 

(5%)

1.

See Non-IFRS financial measures.

2.

EBITDA is defined as ’net profit’, adjusted for ‘income taxes’, ‘financial items’, ‘depreciation and amortisation’ and ‘impairment losses and reversals’.

3.

See Financial definitions and ratios.

4.

Total dividend for the year including interim dividend of DKK 3.75 per share, corresponding to DKK 16,663 million, which was paid in August 2025. The remaining DKK 7.95 per share, corresponding to DKK 35,312 million, will be paid subject to approval at the Annual General Meeting in March 2026.

5.

Total number of patients reached by obesity and diabetes products.

6.

GHG: Greenhouse Gas.